C2N Partners With LSI Medience for Alzheimer’s Test
St. Louis, Missouri, USA, and Tokyo, Japan, November 10, 2026 C2N Diagnostics has entered a strategic partnership with LSI...
C2N Diagnostics
Advertisement
Implantica Wins FDA Approval for RefluxStop® in U.S.
Stockholm, Sweden, August 21, 2026 Implantica AG has announced a major U.S. regulatory milestone after the U.S. Food and...
C2N PrecivityAD2 FDA Clearance Advances Alzheimer’s Testing
NEW YORK, August 21, 2026 The U.S. Food and Drug Administration (FDA) has cleared C2N Diagnostics’ PrecivityAD2 blood test,...
C2N Diagnostics Expands PrecivityAD2 Use in UK Alzheimer’s Diagnosis
ST. LOUIS, July 29, 2026 C2N Diagnostics, LLC announced that researchers in the United Kingdom are integrating its PrecivityAD2®...
Advertisement
